• AI and the Lab of the Future

    May 14 | Bio-IT World | The laboratory of the future does not look at all like what we think of today but will instead be a network of physical and virtual spaces, spanning the entire lifecycle of therapeutic products. Robot-guided molecular and cellular biology labs test predictions of new chemicals generated in the cloud. Biomarkers derived from organs on a chip and federated global clinical trials yield patient-precise clinician reports. Sensors monitor compliance and collect troves of data over time. In fact, all of these technologies are here today, but the laboratory of the future will learn to connect them into constellations of discovery. More
  • Tailocins Play Starring Role In Atomic-Level Horror Show

    May 13 | Bio-IT World | Large protein nanomachines produced by bacteria to selectively annihilate other members of their microbial community could one day be weaponized for wiping out undesirable inhabitants of the human microbiome known to cause ill health and disease. More
  • St Jude Releases Early Data on Asymptomatic Cases Among Vaccinated Healthcare Workers

    May 12 | Bio-IT World | In a research letter published last week in JAMA, St Jude Children’s Research Hospital researchers reported early findings tracking asymptomatic COVID-19 among vaccinated healthcare workers. The findings will inform both individual vaccination plans as well as institutional screening and testing programs. More
  • Value Of Drug Repurposing May Lie In Host-Directed Therapies

    May 10 | Bio-IT World | The University of California, San Francisco’s (UCSF) Quantitative Biosciences Institute (QBI) spearheaded a six-nation collaborative around COVID-19 that now has 26 potential treatments in clinical trials. More
  • Human Biospecimen Procurement Should Be More User Friendly

    May 06 | Bio-IT WorldWhile the vast majority of R&D procurement may never be as easy as point-and-click, we can look to consumer marketplaces for ideas on how to improve the overall life science buying experience. More
  • Could Death Receptor 5 Antibodies Make A Comeback?

    May 04 | Bio-IT World | Big pharma has invested billions of dollars in developing antibodies targeting death receptor 5 (DR5) over the years in hopes of improving the survival of patients with cancer. While promising when tested in mice in the lab, they invariably failed to show efficacy during phase 2 clinical studies. But researchers at the University of Virginia now have a new theory that could revive them. More
  • Sequencing Project for Developmental Differences, New Data Management Tools, Hyperscale Storage, More

    May 03 | Bio-IT World | NIH grant tackles COVID-19 disparities, St. Jude launches historic expansion, Illumina all in on African Pathogen Genomics Initiative, and new platforms and services to ease drug and vaccine development. Plus: new storage from VAST Data, and new solutions for tracking research papers and patents. More
  • Big Money for Gene Editing, Engineering, Structure-Based Drug Design, and Data Management

    Apr 29 | Bio-IT World | Illumina joins the Gates Foundation in a global pathogen genomics initiative, new money for immune profiling, and Benchling nets $200M for their cloud platform. More
  • Understanding Proteins With Natural Language Processing

    Apr 28 | Bio-IT World | New research from the departments of chemistry and physics at Cambridge University has just helped demonstrate the potential of natural language processing (NLP) for understanding biomolecular condensates. More
  • New Event Launching in June Focusing on AI for Pharmaceuticals

    Apr 26 | Bio-IT World | Bio-IT World and AI Trends are pleased to announce DECODE: AI for Pharmaceuticals, June 7-9, 2021, the first cross-functional conference to uncover AI’s true value for the pharmaceutical sector, while also focusing on data strategies, organizational change management, and implementation best practices. More
View more articles
Bio IT World Lead Gen


Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!


Digital Therapeutics: Taking digital health to a new level
Benchling is the most widely-adopted life sciences R&D cloud. Accelerate, measure, and forecast R&D – from discovery through bioprocessing – all in one place. It’s a fully unified platform that centralizes and standardizes all R&D data, so you can spend less time fighting with legacy software, and more time reaching breakthrough discoveries.
Read more here!